Home/Hedge Fund Intelligence/Celldex Therapeutics, Inc.
Nasdaq: CLDXStockForm 13F30 Jun 2026

Hedge funds that hold Celldex Therapeutics, Inc. New Nasdaq: CLDX

New · CUSIP 15117B202 · who reports it, how much, and how much it matters to them

31 of the 720 hedge fund managers we track reported shares of Celldex Therapeutics, Inc. (Nasdaq: CLDX) on Form 13F for 30 June 2026. Between them they reported USD 704m. The largest position belongs to Kynam Capital Management, at USD 198m.

Managers reporting it31of 720 we track
Value they reportUSD 704mshares only, 30 Jun 2026
Funds they run370with a file on PPLI.com
Largest positionUSD 198mKynam Capital Management
Typical weight0.2%median share of a manager's book
Heaviest weight10.9%Kynam Capital Management

Compiled from SEC Form 13F filings · Hedge Fund Intelligence, PPLI.com · updated

Form 13F is filed by the manager and covers all of its accounts, so a position here belongs to the firm, not to any one fund. Not investment advice.

13F
What this page is

A list of every manager in our coverage that reported this share at the end of the quarter, taken from the filings themselves. Short positions and options are not in it.

Who holds it

31 managers, USD 704m between them

Taken from each manager's Form 13F for 30 June 2026. A manager appears here if it reported the shares themselves; positions held only through options are left out.

Every manager that reports Celldex Therapeutics, Inc., largest position first

The bar and the percentage show how much of the manager's reported 13F book the position makes up. Each name opens that manager's largest fund on PPLI.com, where the rest of its book is listed.

#ManagerValue reportedShare of its book
1Kynam Capital Management1 fund on PPLI.comUSD 198m10.9%
2Deep Track Capital1 fund on PPLI.comUSD 109m1.6%
3Logos Global Management1 fund on PPLI.comUSD 78m3.4%
4Eversept Partners3 funds on PPLI.comUSD 66m3.4%
5Baker Bros. Advisors2 funds on PPLI.comUSD 44m0.2%
6Millennium Management6 funds on PPLI.comUSD 44m0.0%
7Rock Springs Capital Management2 funds on PPLI.comUSD 26m1.3%
8Two Sigma Investments35 funds on PPLI.comUSD 25m0.0%
9Braidwell12 funds on PPLI.comUSD 16m0.6%
10Redmile Group10 funds on PPLI.comUSD 16m1.1%
11Palo Alto Investors6 funds on PPLI.comUSD 15m2.1%
12PFM Health Sciences3 funds on PPLI.comUSD 13m1.1%
13Superstring Capital Management1 fund on PPLI.comUSD 11m6.8%
14Sphera Funds Management1 fund on PPLI.comUSD 9m1.2%
15Cinctive Capital Management5 funds on PPLI.comUSD 5.4m0.2%
16Boothbay Fund Management2 funds on PPLI.comUSD 5.2m0.1%
17Suvretta Capital Management4 funds on PPLI.comUSD 4.5m0.1%
18POINT72 Asset Management17 funds on PPLI.comUSD 4.4m0.0%
19HighVista Strategies27 funds on PPLI.comUSD 3.2m0.7%
20Dafna Capital Management6 funds on PPLI.comUSD 2.5m0.5%
21Burkehill Global Management5 funds on PPLI.comUSD 1.9m0.1%
22Aquatic Capital Management3 funds on PPLI.comUSD 1.6m0.1%
23Engineers Gate Manager1 fund on PPLI.comUSD 1.3m0.0%
24Capital Fund Management S.A.12 funds on PPLI.comUSD 1.1m0.0%
25Balyasny Asset Management25 funds on PPLI.comUSD 979,0000.0%
26Verdad Advisers6 funds on PPLI.comUSD 770,0000.7%
27D. E. Shaw & Co.15 funds on PPLI.comUSD 663,0000.0%
28Capstone Investment Advisors25 funds on PPLI.comUSD 440,0000.0%
29Brevan Howard Capital Management39 funds on PPLI.comUSD 303,0000.0%
30Magnetar Financial93 funds on PPLI.comUSD 296,0000.0%
31The Quarry1 fund on PPLI.comUSD 3,1630.0%
Next: where it matters most
Where it matters most

For Kynam Capital Management it is 10.9% of the book

A large manager can hold a great deal of a share and barely notice it. This table turns the question round and ranks managers by how much of their own book the position takes up.

#ManagerValue reportedShare of its book
1Kynam Capital ManagementUSD 198m10.9%
2Superstring Capital ManagementUSD 11m6.8%
3Eversept PartnersUSD 66m3.4%
4Logos Global ManagementUSD 78m3.4%
5Palo Alto InvestorsUSD 15m2.1%
6Deep Track CapitalUSD 109m1.6%
7Rock Springs Capital ManagementUSD 26m1.3%
8Sphera Funds ManagementUSD 9m1.2%
9PFM Health SciencesUSD 13m1.1%
10Redmile GroupUSD 16m1.1%
Next: how to read this
How to read this

What a 13F list can and cannot tell you

  • It is the manager's filing, not a fund's. Form 13F covers every account a firm runs. We cannot say which of its funds holds the shares.
  • It is a snapshot. The list shows the last day of the quarter. A manager may have bought or sold since, and trading inside the quarter leaves no trace.
  • It shows one side. Short positions, swaps and shares listed outside the United States are not reported, so a manager on this list may be hedged or net short.
  • It covers the managers we track. Our coverage is 720 managers of hedge and private funds. Banks, index funds and other institutions that file Form 13F are not counted here.
Next: questions
Questions

Questions about who holds Celldex Therapeutics, Inc.

What is the ticker symbol of Celldex Therapeutics, Inc.?

Celldex Therapeutics, Inc. trades under the symbol CLDX on the Nasdaq. Its CUSIP, the code used on Form 13F, is 15117B202.

Which hedge funds own Celldex Therapeutics, Inc. (Nasdaq: CLDX)?

31 of the 720 hedge fund managers PPLI.com tracks reported Celldex Therapeutics, Inc. shares on Form 13F for 30 June 2026. The largest reported positions were held by Kynam Capital Management (USD 198m), Deep Track Capital (USD 109m), Logos Global Management (USD 78m), Eversept Partners (USD 66m) and Baker Bros. Advisors (USD 44m).

How many hedge funds hold Celldex Therapeutics, Inc.?

31 managers in our coverage reported it, and between them they run 370 funds with a file on PPLI.com. The count is of managers, because Form 13F is filed by the firm and not by each fund.

Which manager has the most riding on Celldex Therapeutics, Inc.?

Kynam Capital Management, where the position was 10.9% of the reported 13F book at 30 June 2026.

Does this show who is short Celldex Therapeutics, Inc.?

No. Form 13F reports long positions in U.S.-listed shares and options. Short positions are not disclosed in it.

Important information

Positions are taken by PPLI.com from Form 13F filings with the U.S. Securities and Exchange Commission for the quarter shown. They are reported by each manager, cover all of its accounts and may have changed since. PPLI.com has no relationship with Celldex Therapeutics, Inc. or with the managers listed.

Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy or sell any security. To report an error, write to the editor.

Private consultation →
Step 1 of 2

Tell us about yourself

Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.

✦Research assistant
✦PPLI.comResearch assistant
Explore PPLI questions and suitability factors
Ask a general question about PPLI, or explore the factors that affect suitability. Treat the answer as a starting point and check the linked sources.
Use the research with your own tax, legal and insurance advisers.
Preparing an answer
AI assistant. Educational information only. It does not determine eligibility or provide personal tax, legal, investment or insurance advice.